Two-year results for aflibercept 8 mg from pivotal photon trial demonstrate durable vision gains at extended dosing intervals in diabetic macular edema

89% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals through two years of those assigned to a 16-week dosing regimen at baseline, 83% maintained ≥16-week dosing intervals through two years many patients met the extension criteria for even longer dosing intervals, including 43% for ≥20-week intervals and 27% for 24-week intervals visual gains and safety of aflibercept 8 mg remained consistent with the established profile of eylea ® (aflibercept) 2 mg injection tarrytown, ny, june 27, 2023 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced top-line, two-year (96 weeks) data for aflibercept 8 mg from the pivotal photon trial in patients with diabetic macular edema (dme). during the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing intervals (after three initial monthly doses) and were able to shorten or extend dosing intervals if pre-specified criteria were met.
REGN Ratings Summary
REGN Quant Ranking